Abstract
Two substances of the benzoquinolizine group have different effects on depletion of brain catecholamines. While tetrabenazine (intravenous) produces a decrease in the brain amine concentration, benzquinamide (intravenous, supplied by Pfizer Argentina, S.A.) produces a rise in the serotonin- and noradrenaline-level (5 HT: 0.65 γ/g; control: 0.57 and noradrenaline: 0.63 γ/g; control: 0.39).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burstein, Ch. L. (in the press).
de Palol, J., and Lemberg, A., Nature, 194, 482 (1962).
Launoy, L., and Nicolle, P., C.R. Soc. Biol., Paris, 99, 198.
Hojman, D., Lemberg, A., de Palol, J., and Rubin, B., paper presented to the Argentine Soc. Pathol. (1960).
Hojman, D., Lemberg, A., de Palol, J., and Rubin, B., Rev. Clin. Med. Espanola, 87, No. 1 (1962).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DE PALOL, J. Effect of Benzquinamide on Blood Pressure. Nature 199, 1102–1103 (1963). https://doi.org/10.1038/1991102a0
Issue Date:
DOI: https://doi.org/10.1038/1991102a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
